Former FDA Commissioner Margaret Hamburg talks about her experience as Commissioner of the FDA.
Friends of Cancer Research and the Engelberg Center for Health Care Reform at Brookings co-hosted discussions on critical issues in cancer care.
Friends of Cancer Research is our country's leading voice in advocating for policies and solutions that will get treatments to patients in the safest and quickest way posible.
Researchers, drug developers, and patient advocates share their thoughts about Lung-MAP
The FDA's Breakthrough Therapy program continues to accelerate the development and approval of groundbreaking new therapies.
Friends of Cancer Research's 2014 Annual Report is now available for download.
Patients, drug developers, and regulators discussed Breakthrough Therapy's progress at our May briefing
AR101 - (Aimmune)
for oral immunotherapy of peanut-allergic children and adolescents 4-17 years of age
SER-109 - (Seres)
for the prevention of recurrent Clostridium difficile infection (CDI)
ACTEMRA/RoACTEMRA - (Genentech/Roche)
for the treatment of systemic sclerosis
FRIENDS OF CANCER RESEARCH1800 M Street NW Suite 1050 | Washington, DC 20036202.944.6700